CCO Think Tank: Emerging HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecologic Malignancies

Clinical commentary, downloadable slides, and on-demand text modules on biomarker testing, recent data, and clinical management of adverse events associated with antibody–drug conjugate therapies in patients with genitourinary, gastrointestinal, and gynecologic cancers.

Share

Program Content

Activities

Think Tank on ADCs: GU, GI, and GYN
Think Tank on Emerging HER2-Targeted ADCs in Genitourinary, Gastrointestinal, and Gynecologic Malignancies
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: March 22, 2024

Activities

HER2 ADCs: GU Malignancies
Emerging HER2-Targeted Antibody–Drug Conjugates in Genitourinary Malignancies
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: April 08, 2024

Expires: October 07, 2024

HER2 Targeted ADCs: GI Cancers
Emerging HER2-Targeted Antibody Drug Conjugates in Gastrointestinal Malignancies
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: April 09, 2024

Expires: October 08, 2024

HER2 ADCs in Gynecologic Cancers
Emerging HER2-Targeted Antibody–Drug Conjugates in Gynecologic Cancers
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: May 09, 2024

Expires: November 08, 2024

Activities

HER2-Targeted ADCs: GI Cancers
CCO Think Tank on Emerging HER2-Targeted ADCs: Gastrointestinal Malignancies
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 20, 2024

Expires: March 19, 2025

HER2 ADCs: GU Malignancies
CCO Think Tank on Emerging HER2-Targeted ADCs: Genitourinary Malignancies
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: March 22, 2024

Expires: March 21, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.